FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036703045> ?p ?o ?g. }

• W2036703045 endingPage "89" @default.
• W2036703045 startingPage "84" @default.
• W2036703045 abstract "No AccessJournal of UrologyAdult urology1 Jan 2007Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma Chia-Chi Lin, Chih-Hung Hsu, Chao-Yuan Huang, Ann-Lii Cheng, Nicholas J. Vogelzang, and Yeong-Shiau Pu Chia-Chi LinChia-Chi Lin Department of Oncology, Taipei, Taiwan National Taiwan University Hospital and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan Equal study contribution. More articles by this author , Chih-Hung HsuChih-Hung Hsu Department of Oncology, Taipei, Taiwan National Taiwan University Hospital and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan Equal study contribution. More articles by this author , Chao-Yuan HuangChao-Yuan Huang Department of Urology, Taipei, Taiwan More articles by this author , Ann-Lii ChengAnn-Lii Cheng Department of Oncology, Taipei, Taiwan Department of Internal Medicine, Taipei, Taiwan National Taiwan University Hospital and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan More articles by this author , Nicholas J. VogelzangNicholas J. Vogelzang Nevada Cancer Institute, Las Vegas, Nevada More articles by this author , and Yeong-Shiau PuYeong-Shiau Pu Department of Urology, Taipei, Taiwan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2006.08.058AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Conventional chemotherapy for urothelial carcinoma, such as methotrexate, vinblastine, doxorubicin and cisplatin, is associated with significant toxicity. We have previously reported a low toxicity and yet moderately active regimen containing weekly infusional cisplatin and high dose 5-fluorouracil/leucovorin for advanced urothelial carcinoma. We tested the efficacy and toxicity of adding paclitaxel to that regimen. Materials and Methods: Between April 2000 and December 2004, 44 patients with a median age of 66 years with metastatic urothelial carcinoma were enrolled. The paclitaxel, cisplatin and high dose 5-fluorouracil/leucovorin regimen consisted of 70 mg/m2 paclitaxel daily as a 1-hour infusion on days 1 and 8, 35 mg/m2 cisplatin daily as a 24-hour infusion on days 2 and 9, 2,000 mg/m2 5-fluorouracil daily and 300 mg/m2 leucovorin daily as a 24-hour infusion on days 2 and 9. The cycles repeated every 21 days. A total of 25 patients (64%) had a creatinine clearance of 35 to 60 ml per minute. Results: A total of 210 cycles (mean 4.8 per patient) were administered. Of the 40 patients eligible for response evaluation 11 (28%) and 19 (48%) were complete and partial responders with an overall response rate of 75% (95% CI 61 to 89). Median overall and progression-free survival in the whole group was 17.0 (95% CI 13.7 to 20.3) and 8.3 months (95% CI 6.4 to 10.2), respectively. Two-year disease-free survival was 15%. Grade 3 or 4 anemia, leukopenia and thrombocytopenia occurred at 23, 30 and 12 cycles, respectively. Nonhematological toxicity included infection, vomiting and diarrhea, etc. There were 2 treatment related deaths. Conclusions: Paclitaxel, cisplatin and high dose 5-fluorouracil/leucovorin is an active regimen against metastatic urothelial carcinoma which has an acceptable toxicity profile. References 1 : Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol1995; 153: 894. Link, Google Scholar 2 : Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol1997; 15: 2564. Google Scholar 3 : A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol1990; 8: 1050. Google Scholar 4 : Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol2005; 23: 4602. Google Scholar 5 : Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol1999; 17: 3173. Google Scholar 6 : Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)—a very effective regimen with good patients’ compliance for advanced gastric cancer. Anticancer Res1998; 18: 1267. Google Scholar 7 : A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res2001; 21: 1385. Google Scholar 8 : Biochemical modulation of fluorouracil:: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol1989; 7: 1407. Google Scholar 9 : Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res1999; 5: 2620. Google Scholar 10 : Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma—an effective regimen with low toxicity. Cancer2006; 106: 1269. Google Scholar 11 : Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anticancer Drugs1998; 9: 203. Google Scholar 12 : A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer2000; 83: 458. Google Scholar 13 : Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol1994; 12: 2264. Google Scholar 14 : Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol2001; 19: 4216. Google Scholar 15 : Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells. J Urol2001; 166: 2082. Google Scholar 16 : Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol1991; 9: 1692. Google Scholar 17 : Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol2000; 164: 1538. Link, Google Scholar 18 : Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol2000; 18: 1058. Google Scholar 19 : Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer1996; 74: 704. Google Scholar 20 : Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium Spanish Oncology Genitourinary Group. J Clin Oncol2000; 18: 3274. Google Scholar 21 : Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer2000; 88: 1671. Google Scholar 22 : Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol2002; 13: 243. Google Scholar 23 : Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer2005; 103: 2298. Google Scholar 24 : Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol2001; 19: 2527. Google Scholar © 2007 by American Urological AssociationFiguresReferencesRelatedDetails Volume 177Issue 1January 2007Page: 84-89 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordsneoplasm metastasistransitional cellurotheliumcarcinomabladdercytotoxinstoxicityAcknowledgmentsHsiao-Yi Keng and Hui-Jung Chao, Department of Oncology, and Ming-Kuen Lai, Hong-Jeng Yu and Shih-Chieh Chueh, Department of Urology, National Taiwan University Hospital provided patient care.MetricsAuthor Information Chia-Chi Lin Department of Oncology, Taipei, Taiwan National Taiwan University Hospital and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan Equal study contribution. More articles by this author Chih-Hung Hsu Department of Oncology, Taipei, Taiwan National Taiwan University Hospital and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan Equal study contribution. More articles by this author Chao-Yuan Huang Department of Urology, Taipei, Taiwan More articles by this author Ann-Lii Cheng Department of Oncology, Taipei, Taiwan Department of Internal Medicine, Taipei, Taiwan National Taiwan University Hospital and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan More articles by this author Nicholas J. Vogelzang Nevada Cancer Institute, Las Vegas, Nevada More articles by this author Yeong-Shiau Pu Department of Urology, Taipei, Taiwan More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2036703045 created "2016-06-24" @default.
• W2036703045 creator A5004942811 @default.
• W2036703045 creator A5017953971 @default.
• W2036703045 creator A5020674154 @default.
• W2036703045 creator A5030951075 @default.
• W2036703045 creator A5059219836 @default.
• W2036703045 creator A5090591171 @default.
• W2036703045 date "2007-01-01" @default.
• W2036703045 modified "2023-10-17" @default.
• W2036703045 title "Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma" @default.
• W2036703045 cites W1530228579 @default.
• W2036703045 cites W1723772693 @default.
• W2036703045 cites W1820014750 @default.
• W2036703045 cites W1847455118 @default.
• W2036703045 cites W1857682357 @default.
• W2036703045 cites W1939723756 @default.
• W2036703045 cites W1941332786 @default.
• W2036703045 cites W1945195571 @default.
• W2036703045 cites W1946759281 @default.
• W2036703045 cites W2027887565 @default.
• W2036703045 cites W2041173222 @default.
• W2036703045 cites W2047108938 @default.
• W2036703045 cites W2064752751 @default.
• W2036703045 cites W2076723564 @default.
• W2036703045 cites W2081911999 @default.
• W2036703045 cites W2087201383 @default.
• W2036703045 cites W2091646887 @default.
• W2036703045 cites W2103133513 @default.
• W2036703045 cites W2103257412 @default.
• W2036703045 cites W2240844634 @default.
• W2036703045 cites W4323966482 @default.
• W2036703045 doi "https://doi.org/10.1016/j.juro.2006.08.058" @default.
• W2036703045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17162009" @default.
• W2036703045 hasPublicationYear "2007" @default.
• W2036703045 type Work @default.
• W2036703045 sameAs 2036703045 @default.
• W2036703045 citedByCount "23" @default.
• W2036703045 countsByYear W20367030452013 @default.
• W2036703045 countsByYear W20367030452014 @default.
• W2036703045 countsByYear W20367030452016 @default.
• W2036703045 countsByYear W20367030452017 @default.
• W2036703045 countsByYear W20367030452019 @default.
• W2036703045 crossrefType "journal-article" @default.
• W2036703045 hasAuthorship W2036703045A5004942811 @default.
• W2036703045 hasAuthorship W2036703045A5017953971 @default.
• W2036703045 hasAuthorship W2036703045A5020674154 @default.
• W2036703045 hasAuthorship W2036703045A5030951075 @default.
• W2036703045 hasAuthorship W2036703045A5059219836 @default.
• W2036703045 hasAuthorship W2036703045A5090591171 @default.
• W2036703045 hasConcept C121608353 @default.
• W2036703045 hasConcept C126322002 @default.
• W2036703045 hasConcept C126894567 @default.
• W2036703045 hasConcept C143998085 @default.
• W2036703045 hasConcept C2776694085 @default.
• W2036703045 hasConcept C2777292972 @default.
• W2036703045 hasConcept C2778239845 @default.
• W2036703045 hasConcept C2780352672 @default.
• W2036703045 hasConcept C2780456651 @default.
• W2036703045 hasConcept C2911057145 @default.
• W2036703045 hasConcept C3019882237 @default.
• W2036703045 hasConcept C71924100 @default.
• W2036703045 hasConceptScore W2036703045C121608353 @default.
• W2036703045 hasConceptScore W2036703045C126322002 @default.
• W2036703045 hasConceptScore W2036703045C126894567 @default.
• W2036703045 hasConceptScore W2036703045C143998085 @default.
• W2036703045 hasConceptScore W2036703045C2776694085 @default.
• W2036703045 hasConceptScore W2036703045C2777292972 @default.
• W2036703045 hasConceptScore W2036703045C2778239845 @default.
• W2036703045 hasConceptScore W2036703045C2780352672 @default.
• W2036703045 hasConceptScore W2036703045C2780456651 @default.
• W2036703045 hasConceptScore W2036703045C2911057145 @default.
• W2036703045 hasConceptScore W2036703045C3019882237 @default.
• W2036703045 hasConceptScore W2036703045C71924100 @default.
• W2036703045 hasIssue "1" @default.
• W2036703045 hasLocation W20367030451 @default.
• W2036703045 hasLocation W20367030452 @default.
• W2036703045 hasOpenAccess W2036703045 @default.
• W2036703045 hasPrimaryLocation W20367030451 @default.
• W2036703045 hasRelatedWork W1994109701 @default.
• W2036703045 hasRelatedWork W2030595392 @default.
• W2036703045 hasRelatedWork W2053380829 @default.
• W2036703045 hasRelatedWork W2600921209 @default.
• W2036703045 hasRelatedWork W2972369539 @default.
• W2036703045 hasRelatedWork W3152185824 @default.
• W2036703045 hasRelatedWork W3180939467 @default.
• W2036703045 hasRelatedWork W4250542463 @default.
• W2036703045 hasRelatedWork W4283516900 @default.
• W2036703045 hasRelatedWork W4380149984 @default.
• W2036703045 hasVolume "177" @default.
• W2036703045 isParatext "false" @default.
• W2036703045 isRetracted "false" @default.
• W2036703045 magId "2036703045" @default.
• W2036703045 workType "article" @default.